Gonorrhea Treatment. If you have this STD, your doctor will likely prescribe two antibiotics: ceftriaxone and either azithromycin (Zithromax, Zmax) or doxycycline (Monodox, Vibramycin).
Full Answer
Which antibiotics are used to treat gonorrhea?
Mar 31, 2022 · Official Answer. From the 2015 Sexually Transmitted Disease (STD) guidelines, the CDC recommends treatment for a gonorrhea-chlamydia coinfection with azithromycin ( Zithromax) 1 gram given orally in a single dose, plus ceftriaxone ( Rocephin) 250 mg given intramuscularly as first-line therapy.
What is included in the monitoring of Gonorrhea treatment?
Mar 31, 2022 · Untreated gonorrhea in pregnant women may cause blindness in newborns. In some cases, ceftriaxone poses problems. Since is it a cephalosporin, some people are allergic to it if they are allergic to penicillin. An option is to look for the next best antibiotics for gonorrhea. Medications like doxycycline or clarithromycin could be used instead. Another approach is to …
What is the first-line treatment for gonorrhea?
CDC recommends a single dose of 500 mg of intramuscular ceftriaxone. Alternative regimens are available when ceftriaxone cannot be used to treat urogenital or rectal gonorrhea. Although medication will stop the infection, it will not repair any permanent damage done by the disease. Antimicrobial resistance in gonorrhea is of increasing concern, and successful treatment of …
What is the cause of gonorrhea Quizlet?
In 1993, ciprofloxacin, a fluoroquinolone, and two cephalosporins (ceftriaxone and cefixime) were the recommended treatments for gonorrhea. However, in the late 1990s and early 2000s, ciprofloxacin resistance was detected in Hawaii and the West Coast.
What antibiotics are used to treat gonorrhea?
What is the medical treatment of a patient suspected to have N gonorrhea?
What is best treatment for gonorrhea?
Can azithromycin and doxycycline treat gonorrhea?
Why do doctors recommend probiotics?
Because antibiotics kill both good and bad bacteria in the body, physicians may suggest probiotic supplements to replenish beneficial bacteria.
Is pharyngeal gonorrhea common in teens?
Pharyngeal gonorrhea may be prevalent in teens who engage in oral sexual activities in groups.
Can you inject ceftriaxone for gonorrhea?
An injection of ceftriaxone might be all that's needed for basic gonorrheal infection.
What is the best treatment for gonorrhea?
Adults with gonorrhea are treated with antibiotics. Due to emerging strains of drug-resistant Neisseria gonorrhoeae, the Centers for Disease Control and Prevention recommends that uncomplicated gonorrhea be treated with the antibiotic ceftriaxone — given as an injection — with oral azithromycin (Zithromax).
What antibiotics are given to allergic people?
If you're allergic to cephalosporin antibiotics, such as ceftriaxone, you might be given oral gemifloxacin (Factive) or injectable gentamicin and oral azithromycin.
What test can help identify bacteria in your urethra?
Urine test. This can help identify bacteria in your urethra.
Can gonorrhea be tested for chlamydia?
Testing for other sexually transmitted infections. Your doctor may recommend tests for other sexually transmitted infections. Gonorrhea increases your risk of these infections, particularly chlamydia, which often accompanies gonorrhea.
What is antibiotic resistant gonorrhea?
Antibiotic-Resistant Gonorrhea: An Overview. Antibiotic resistance is the ability of bacteria to resist the effects of the drugs used to treat them. This means the bacteria are no longer killed by a drug that used to kill them before. The bacteria are then free to keep multiplying.
Where to report gonorrhea?
In the United States, reports of apparent failures of gonorrhea to respond to treatment with CDC-recommended therapies should be reported to Sancta St Cyr, MD, MPH ( [email protected]; 404-718-5447). Surveillance and Data Management Branch, Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop E02, Atlanta, GA 30333.
Does gonorrhea decrease susceptibility to antibiotics?
Gonorrhea has decreased susceptibility to a given antibiotic when laboratory results indicate that higher-than-expected levels of an antibiotic are needed to stop its growth.
Does the CDC recommend gonorrhea culture?
CDC recommends that all state and local health department labs maintain or develop the capacity to perform gonorrhea culture, or form partnerships with experienced laboratories that can perform this type of testing.
Is gonorrhea resistant to antibiotics?
The bacteria are then free to keep multiplying. Gonorrhea has developed resistance to nearly all of the antibiotics used for its treatment. We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common infection.
Is there a first line treatment for cephalosporin?
Currently, just one regimen is recommended as first-line treatment for go norrhea: a single 500 mg dose of the injectable cephalosporin, ceftriaxone.
Does the CDC monitor antibiotic resistance?
CDC continues to monitor antibiotic resistance to cephalosporins and other drugs.
What is the most common site of N. gonorrhoeae infection?
Urogenital Infections. The most common site of N. gonorrhoeae infection is the urogenital tract . In women it can infect the endocervix and, if an ascending infection develops, it can cause PID. Men may develop urethritis and, occasionally, epididymitis.
What is the treatment for urogenital gonococcal infection?
Treatments for uncomplicated urogenital, anorectal, or pharyngeal gonococcal infections include cephalosporins and fluoroquinolones. Fluoroquinolones should not be used in patients who live in or may have contracted gonorrhea in Asia, the Pacific islands, or California, or in men who have sex with men.
What is the most common site of Neisseria gonorrhoeae?
The most common site of Neisseria gonorrhoeae infection is the urogenital tract. Men with this infection may experience dysuria with penile discharge, and women may have mild vaginal mucopurulent discharge, severe pelvic pain, or no symptoms. Other N. gonorrhoeae infections include anorectal, conjunctival, pharyngeal, and ovarian/uterine.
What is the most commonly infected joint?
The most commonly infected joints include wrists, ankles, and the joints of the hands and feet. Urogenital N. gonorrhoeae infections can be diagnosed using culture or nonculture (e.g., the nucleic acid amplification test) techniques. When multiple sites are potentially infected, culture is the only approved diagnostic test.
What percentage of women with gonorrhea have a PID?
Ten to 20 percent of women with gonorrhea develop ascending infection that causes acute salpingitis with or without endometritis, also known as PID. 2 Presentations may range from no symptoms to severe abdominal pain with a high fever. PID can negatively affect fertility, causing infertility in 15 percent of patients 2; 50 percent of patients who have three or more episodes of PID develop infertility. 2
How long does it take for a urogenital infection to show symptoms?
Unlike women, men with urogenital infections are usually symptomatic. The normal incubation period is two to six days after exposure. Symptoms include purulent penile discharge and dysuria. The discharge may present at the meatus, which may be erythematous. Discharge may be expressed by milking the penis.
Can gonorrhea cause urogenital sex?
Neisseria gonorrhoeae infections may present as a broad range of symptoms and can affect urogenital, anorectal, pharyngeal, and conjunctival areas.
Which is more prevalent, chlamydia or gonorrhea?
Overall, chlamydia is more prevalent than gonorrhea, but both diseases predominantly affect the 20- to 24-year-old age group.
What happens to lactobacilli after puberty?
After puberty, lactobacilli dominate discouraging growth of other microbes.
What is the flushing action of urine?
The flushing action of urine is a defense mechanism that prevents microbial invasion of the urinary system.
What antimicrobials are used for gonorrhea?
Prior to 2007, fluoroquinolones were the preferred class of antimicrobials for the treatment of gonorrhea; however, reports surfaced of N gonorrhoeae infection with decreasing susceptibilities and frank resistance. In addition, United States gonococcal strains with elevated MICs to cefixime are likely to be resistant to tetracyclines but susceptible to azithromycin.
When to do a test of cure for pharyngeal gonorrhea?
A test-of-cure is unnecessary for persons with uncomplicated infection, except for persons with pharyngeal gonorrhea, a test-of-cure is recommended using culture or nucleic acid amplification tests 7–14 days after initial treatment , regardless of the treatment regimen. CDC advises that clinicians should perform susceptibility testing in patients who fail to respond to treatment and notify their local public health STD program. [ 61]
How to prevent gonococcal infection?
The prevention of gonococcal infections is based on education, mechanical or chemical prophylaxis, and early diagnosis and treatment. Condoms offer partial protection, while effective antibiotics taken in therapeutic doses immediately before or soon after exposure can mediate an infection. Several studies have shown that male circumcision status had no statistically significant impact on susceptibility to or acquisition of gonorrhea. [ 67, 68]
When did the CDC change the guidelines for gonorrhea?
In August 2012, the CDC announced changes to the 2010 sexually transmitted disease guidelines for gonorrhea treatment. The Gonococcal Isolate Surveillance Project (GISP) described a decline in cefixime susceptibility among urethral N gonorrhoeae isolates in the United States during 2006-2011. Because of cefixime’s susceptibility, new guidelines were issued that no longer recommend oral cephalosporins for first-line gonococcal infection treatment. [ 63]
What is the decision to treat gonorrhea?
The main decision once a diagnosis of gonorrhea has been made, either definitively or presumptively, is whether to treat the patient as an outpatient or to hospitalize him or her.
How long after a pharyngeal gonorrhea test?
A test-of-cure is unnecessary for persons with uncomplicated infection, except for persons with pharyngeal gonorrhea, a test-of-cure is recommended using culture or nucleic acid amplification tests 7–14 days after initial treatment, regardless of the treatment regimen.
What is the decision made when a patient is diagnosed with gonorrhea?
The main decision once a diagnosis of gonorrhea has been made, either definitively or presumptively, is whether to treat the patient as an outpatient or to hospitalize him or her.
What is the role of gonococcus in STI?
As a strict human pathogen, it is not surprising that the gonococcus has developed multiple mechanisms to cope with the innate and adaptive immunity systems that are typically associated with the host defense. For example, to escape the immunological defense system of the host, the gonococcus uses mechanisms such as antigenic and phase variation of outer membrane structures, blocking antibodies, molecular mimicry, and inhibition and/or induction of apoptosis.3This ability of gonococci to escape host defensive systems emphasizes its adaptive ability and provides a framework for understanding the evolutionary processes used by gonococci to resist the myriad of antibiotics used to treat infections for the past 70 years.
What is the future of antibiotic resistance?
Clearly, the massive global public health problem of antibiotic resistance in general has caught the attention of many. Any solution will require the joint efforts of governments, industry, academia and the healthcare establishments. With respect to gonorrhea and other agents of STIs, we must first convince those in the decision-making process that the reproductive health of the world’s population will be severely compromised if we do not act soon. The recent emergence of the first gonococcal strain expressing high-level resistance to ceftriaxone,29,30the last remaining option for empirical first-line treatment of gonorrhea, should be the “wake-up call.” In the meantime, in order to at least delay widespread dissemination of ceftriaxone-resistant gonococcal strains we need to maximize our active surveillance efforts (perform susceptibility testing of gonococcal isolates and appropriate identification of treatment failures), globally, nationally, and especially at the local level, and use effective antibiotics (of appropriate quality and in optimized dose).1In certain regions, discontinued antibiotics might be used, but this strategy would require a return to the practice of culturing and antibiotic resistance testing in the clinical laboratory, which probably will not be feasible and/or affordable. Advances in molecular diagnostics and rapid genome sequencing efforts can also help to predict antibiotic resistance and ideally also future evolution of resistance. However, in regard to third-generation cephalosporins, such as cefixime and ceftriaxone, sufficient data to accurately correlate the presently known resistance determinants to the MICs of the gonococcal isolates and, further, to the treatment outcome remain lacking. None of this, however, will be effective unless there is a willingness to discuss STIs in the context of the overall healthcare initiatives that currently exist or lie in the future.
How long does it take for penicillin resistance to develop?
The development of penicillin resistance in gonococci is illustrative of how antibiotic pressure and selection can drive resistance; this topic has been extensively reviewed by Shafer et al.4As noted above, the development of chromosomally determined resistance took nearly 40 years and was the result of changes (mutations and gene acquisition) in at least five single locus (or at least in some cases “cooperative loci”). Early work by Sparling and coworkers showed that sequential accumulation of polymorphisms in loci termed penA, mtr, and penBresulted in graded increases in penicillin resistance. The latter two resistance determinants also affect the susceptibility to several other antimicrobials, such as tetracycline, macrolides, and cephalosporins, which are also affected by polymorphisms in penA(see below). penAencodes PBP2, which is the main lethal target for penicillin (and other β-lactam antibiotics) and responsible for peptidoglycan cross-linking at the septum during cell division.37The Spratt laboratory has provided insightful data revealing that a single amino acid insertion (Asp345A) in PBP2 downstream from the penicillin acylation site substantially decreased the affinity for penicillin.38This Asp345A insertion was most probably generated by transformation from donor DNA originating from commensal Neisseria residing in the nasopharynx. The mtr(multiple transferable resistance) determinant was first identified by Maness and Sparling in 197339as a phenotype that resulted in increased, nonspecific resistance of gonococci to a panel of hydrophobic antimicrobials and the less hydrophobic penicillin. Mtr was first thought to decrease the outer membrane permeability of gonococci to these antimicrobials, but is now known to be mainly due to mutations in a gene encoding a transcriptional repressor (MtrR) or its promoter.4,40,41MtrR binds to and represses an adjacent, but divergent, promoter used for transcription of an efflux pump operon (mtrCDE), which encodes a tripartite export system that expels antimicrobials from the bacterial periplasmic space.4Veal et al.42showed that overexpression of the mtrCDE-encodedefflux pump is important in strains expressing high-level penicillin resistance and determined that mutations that abrogate pump function can result in a mutant strain expressing hypersusceptibility to penicillin; note that this observation supports the concept that inhibitors of drug efflux pumps could allow for a return of previously used and now discarded antibiotics. The penBresistance determinant is due to specific mutations in the gene encoding the major outer membrane porin protein termed PorB1b.43This porin, PorB, exists in two allelic forms termed PorB1a and PorB1b. PorB1b–producing gonococci are often slightly less susceptible than PorB1a strains to penicillin and penBmutations can further decrease such susceptibility. Specific amino acid replacements in loop 3 (G120K and A121D) of PorB1b have been linked to the penBresistance determinant.44These mutations were thought to decrease entry of penicillin through the PorB1b porin,43,44but a conflicting view has been presented.4,45,46Interestingly, penBmutations are only phenotypically evident when the strain has a coresident mtrRmutation, suggesting some interaction between PorB1b and the MtrCDE efflux pump.4,45,46At least two additional mutations are needed for penicillin resistance (MIC of ≥2 µg/mL), but these are less well understood. Specific mutation in ponA (ponA1; results in the amino acid replacement L421P) causes a decreased affinity for penicillin to the encoded PBP1, and further decreased susceptibility to penicillin.47Finally, the penC(currently more commonly named pilQ2) mutation occurs in the pilQgene, which encodes the secretin PilQ of the type IV pilin.47,48pilQ2(encoding the amino acid replacement E666K) can decrease the stability of the PilQ doughnut-like multimeric structure in the outer membrane, which seems to decrease entry of penicillin.47,48However, since pilQ2mutations influence proper piliation, which is important for gonococcal disease, it is hard to envision how pilQmutations would afford a selective advantage in the community and accordingly be of importance for wide spread of clinical penicillin resistance.
How do antibiotic resistance determinants spread?
Once established, resistance determinants can be donated to other gonococci largely by transformation, which substantially facilitates spread of resistance alleles. An excellent example of conjugal transfer of DNA into and among gonococci appears to be the transfer of the tetMgene carried on the conjugal plasmid in certain strains. This conjugal plasmid, with or without carriage of the tetMgene, can also display relatively high efficiency in intercellular conjugal transfer of β-lactamase-encoding plasmids between different N. gonorrhoeaestrains, as well as to N. meningitidis, Haemophilus influenzae, and Escherichia coli.31–35However, this conjugal plasmid and its conjugation system is substantially less efficient, compared to the transformation system (see later), and fails to mobilize chromosomal genes. In general, resistance determinants seem to be stably maintained in gonococci even though the antibiotic has been removed from treatment regimen decades earlier. This maintenance of the resistance determinants may be due to the antibiotics used to treat other bacterial infections, inappropriate use of the antibiotic, or antigonococcal agents used topically to prevent STIs and HIV transmission or pregnancy (e.g., the spermicide nonoxynol-9), which could inadvertently maintain selective pressure in the community for resistant strains. However, the persistence may also be because the resistance determinants (i) do not affect the biological fitness (no benefits for the bacteria to get rid of them); (ii) do lower the biological fitness; however, this fitness cost is compensated by second-site mutation (not influencing the resistance); or (iii) the resistance determinants may even cause a higher biological fitness and, in fact, make these clones more successful with regard to transmission and virulence (see later).
Is gonorrhea a bacterial infection?
The strict human pathogen Neisseria gonorrhoeaehas caused gonorrhea for thousands of years, and currently gonorrhea is the second most prevalent bacterial sexually transmitted infection worldwide. Given the ancient nature of N. gonorrhoeaeand its unique obligate relationship with humankind over the millennia, its remarkable ability to adapt to the host immune system and cause repeated infections, and its propensity to develop resistance to all clinically useful antibiotics, the gonococcus is an ideal pathogen on which to study the evolution of bacterial pathogenesis, including antimicrobial resistance, over the long term and within the host during infection. Recently, the first gonococcus displaying high-level resistance to ceftriaxone, identified in Japan, was characterized in detail. Ceftriaxone is the last remaining option for empirical first-line treatment, and N. gonorrhoeaenow seems to be evolving into a true “superbug.” In the near future, gonorrhea may become untreatable in certain circumstances. Herein, the history of antibiotics used for treatment of gonorrhea, the evolution of resistance emergence in N. gonorrhoeae, the linkage between resistance and biological fitness of N. gonorrhoeae, lessons learned, and future perspectives are reviewed and discussed.
Is gonococcus a pathogen?
Its comparative ease of cultivation in the laboratory, the ability to genetically manipulate strains, and recent advances in genomics make the gonococcus an ideal STI pathogen to study in terms of the evolution of antibiotic resistance, including its mechanisms, expressed by such pathogens. It is important to stress that in the absence of effective vaccines, appropriate diagnostics and subsequent effective antibiotic therapy remains the principal method to stop the spread of STIs in the community. Emergence of resistant strains causing an STI can endanger the reproductive health (and in some instances, overall health) of the afflicted when such resistance is not initially evident. Continued sexual encounters by those harboring a resistant strain can result in spread of the pathogen within social networks. Once resistance is determined, alternative and sometimes more expensive or unavailable antibiotics (e.g., in poor countries) are required to cure the infection. During the last 70–80 years, N. gonorrhoeaehas developed resistance to mainly all antimicrobials introduced for treatment of gonorrhea. Worryingly, the antibiotic treatment options now seem to be running out, and in the near future, gonorrhea may become untreatable in certain circumstances (see later).1
Is N. gonorrhoeaenow resistant to ceftriaxone?
gonorrhoeaenow has shown its ability to also develop high-level resistance to ceftriaxone,29,30which is the last remaining option for empirical first-line treatment of gonorrhea; this STI pathogen, therefore, seems to be evolving into a true superbug and, in the near future, may become untreatable in certain circumstances.